NEW YORK — Adaptive Biotechnologies launched its initial public offering today, floating 15 million shares of its common stock at $20 apiece to raise up to $300 million in gross proceeds.
During midday trading, the stock was up 91 percent at $38.20.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
Don't have a 360Dx or GenomeWeb account?Register for Free.
This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.